The use of cyclophosphamide, bortezomib and dexamethasone (CyBorD) is widely accepted in the treatment of AL amyloidosis (AL). Recently, the substitution of dexamethasone by methylprednisolone (CyBorMe) appeared to improve response rates and survival outcomes. All consecutive newly diagnosed AL amyloidosis treated with CyBorMe from 01/19 to 08/20 were evaluated. A historic cohort of patients treated with CyBorD was used for comparison (01/13–08/20). Methylprednisolone was given IV at 500 mg weekly for 4 weeks in the CyBorMe group. 43 patients were treated with CyBorD and 14 with CyBorMe. After a median of 4 cycles of CyBorD and 3 cycles of CyBorMe, Hematological Response was seen in 90.6% and 92.8% of cases, including CR in 28.5% and 35.7%, VGPR in 33.3% and 35.7% and PR in 30.9% and 21.4% for CyBorD and CyBorMe, respectively. Time to first response was faster in the CyBorMe group (4 vs. 6 weeks) and cardiac response was observed in 44% and 31% of patients treated with CyBorMe and CyBorD, respectively. CyBorMe appeared to be efficacious and well tolerated in patients with AL amyloidosis. Prospective studies with CyBorMe in the stage III/IV group are warranted aiming to minimize toxicity.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Vaxman I, Dispenzieri A, Muchtar E, Gertz M (2020) New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Rev 40:100636
Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5):361–369
Venner CP, Lane T, Foard D et al (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119(19):4387–4390
Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al (2012) Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119(19):4391–4394
Palladini G, Sachchithanantham S, Milani P et al (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126(5):612–615
Manwani R, Cohen O, Sharpley F et al (2019) A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 134(25):2271–2280
Mahmood ASS, Harrison S, Manwani R, Sharpley F, Quarta C, Rezk T, Martinez A, Yoong K, Rabin N, Popat R, Kyriacou C, Papanikolau X, D'Sa S, Lachmann H, Whelan C, Gillmore J, Fontana M, Hawkins P, Wechaleckar A (2019) Bortezomib-High dose Methylprednisolone offers improved hematological response and overall survival compared to Bortezomib-Dexamethasone in Systemic Light Chain Amyloidosis. EHA Library. 2019:PB2127. Accessed 2019
Jimenez-Zepeda VH, Duggan P, Neri P, Bahlis NJ (2016) Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience. Clin Lymphoma Myeloma Leuk 16(6):e79-84
Diaz-Pallares C, Lee H, Luider J et al (2020) Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes. Clin Lymphoma Myeloma Leuk 20(6):394–399
Palladini G, Dispenzieri A, Gertz MA et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541–4549
Gertz MA, Comenzo R, Falk RH, et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol, 79(4):319-328
Merlini G, Seldin DC, Gertz MA (2011) Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 29(14):1924–1933
Jiang F, Chen J, Liu H, Li L, Lu W, Fu R (2018) The effect and safety of bortezomib in the treatment of AL amyloidosis: a systematic review and meta-analysis. Indian J Hematol Blood Transfus 34(2):216–226
Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F (2019) Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 9(1):8552
Wechalekar AD, Schonland SO, Kastritis E et al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121(17):3420–3427
Manwani R, Foard D, Mahmood S et al (2018) Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica 103(4):e165–e168
Zoorob RJ, Cender D (1998) A different look at corticosteroids. Am Fam Physician 58(2):443–450
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jimenez-Zepeda, V.H., Lee, H., Fine, N. et al. Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center. Indian J Hematol Blood Transfus (2021). https://doi.org/10.1007/s12288-021-01406-z
- AL amyloidosis
- Organ response